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1  | INTRODUC TION
Parkinson’s disease (PD) is a heterogeneous neurodegenerative 
disorder with a wide spectrum of motor and non-motor features. 
This variability has prompted a number of studies to investigate the 
existence of PD subtypes. It is possible to distinguish three main 
different clinical subtypes with different evolution and prognoses 
according to the predominant motor features: “tremor-dominant” 
(TD), “akinetic-rigid” (AR), also defined as the “postural instability 
gait difficulty” (PIGD) subtype (Zaidel, Arkadir, Israel, & Bergman, 
2009), and “mixed” (MIX), which does not present with one prevail-
ing motor feature.
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Abstract
Background: Parkinson’s disease (PD) is a heterogeneous neurodegenerative disor-
der. It is well established that different motor subtypes of PD evolve with different 
clinical courses and prognoses. The complete psychiatric profile underlying these dif-
ferent phenotypes since the very early stage of the disease is debated.
Aims of the study: We aimed at investigating the psychiatric profile of the three 
motor subtypes of PD (akinetic-rigid, tremor-dominant, and mixed) in de novo drug-
naïve patients with PD.
Methods: Sixty-eight patients with PD, divided into 39 akinetic-rigid (AR), seven 
mixed (MIX), and 22 tremor-dominant (TD) patients underwent a complete assess-
ment of psychiatric, cognitive, and motor symptoms.
Results: No significant differences were found among groups.
Conclusions: Our results suggest that a differentiation of the psychiatric symptoms 
associated with specific motor subtypes of PD is not detectable in de novo drug-
naïve patients. Previous evidence that emerges later along the disease progression 
may be a consequence of the dopaminergic and nondopaminergic damage increase.
K E Y W O R D S
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The studies on patients with PD at late stages of disease showed 
that TD and AR presentations are characterized by different risks 
and severities of specific neuropsychiatric symptoms along the 
disease course, such as depression, apathy, and cognitive impair-
ment. AR subjects show a more rapid clinical progression and are 
at increased risk of developing disability and dementia (Rajput, Voll, 
Rajput, Robinson, & Rajput, 2009). On the other hand, disease pro-
gression of the TD subtype is slower, associated with less cognitive 
decline and lower incidence of complications such as visual halluci-
nations and depression (Oh, Kim, Choi, Sohn, & Lee, 2009; Rajput 
et al., 2008). These different features are supported by pathophysi-
ological investigations showing a more widespread reduction of pal-
lidal and striatal dopamine levels in AR patients, when compared to 
TD (Rajput et al., 2008).
Whilst few studies examined cognitive domains among phe-
notypes in de novo drug-naïve patients with PD (Domellof, Elgh, 
& Forsgren, 2011; Poletti et al., 2012), characterization of psychi-
atric phenomenology is limited to reports of higher alexithymia 
in de novo AR patients (Poletti et al., 2011). Moreover, compre-
hensive neuropsychiatric battery and formal psychiatric diagno-
ses were never applied in de novo patients with PD. In light of 
the recent efforts of Movement Disorder Societies to dissect 
non-motor	profiles	at	different	disease	stages	(Sauerbier,	Jenner,	
Todorova, & Chaudhuri, 2016), here we studied the psychiatric 
profile of the three motor subtypes in early, untreated patients 
with PD.
2  | MATERIAL S AND METHODS
2.1 | Participants
The study was carried out on 68 consecutive antiparkinsonian 
de novo drug-naïve patients with PD according to international 
guidelines. All subjects were enrolled at the Movement Disorder 
Outpatient Services of our Institutions (Fondazione Santa Lucia 
IRCCS, Rome, Italy; Department of Neuroscience, Mental Health 
and Sensory Organs, University “Sapienza,” Sant’Andrea Hospital, 
Rome, Italy; Department of Medicine of Systems, University “Tor 
Vergata,” Rome, Italy; and Neurology Unit, San Giovanni Addolorata 
Hospital, Rome, Italy). Clinical diagnosis of PD was confirmed along a 
36-month follow-up period from symptom onset. Based on different 
onset motor presentations of PD, patients were divided into three 
subgroups according to Kang et al. guidelines (Kang et al., 2005): 
AR (n = 39), TD (n = 22), and MIX (n	=	7).	Subtypes	were	defined	ac-
cording to the ratio of patient’s Unified Parkinson’s Disease Rating 
Scale—Part III (UPDRS-III) tremor score (obtained as sum of Items 20 
and 21 divided by 4) to his or her mean UPDRS akinetic/rigid score 
(sum	of	Items	22–27	and	31	divided	by	15)	such	that	(a)	a	ratio	=	1.0	
equals tremor-dominant; (b) a ratio = 0.80 equals akinetic-rigid; and 
(c) a ratio between 0.80 and 1.0 equals mixed (Kang et al., 2005).
Inclusion criteria were as follows: (a) presentation at the time 
of the first diagnosis of PD, before undergoing antiparkinsonian 
therapy; (b) vision and hearing sufficient for compliance with testing 
procedures;	 (c)	Mini-Mental	State	Examination	 (MMSE)	score	≥26;	
and (d) no dementia according to the Movement Disorder Society 
(MDS) clinical diagnostic criteria.
Exclusion criteria were as follows: (a) the presence of major 
nonstabilized medical illnesses (i.e. diabetes, obstructive pulmo-
nary disease or asthma, hematologic/oncologic disorders, vitamin 
B12 or folate deficiency, pernicious anemia, clinically significant 
and unstable active gastrointestinal, renal, hepatic, endocrine or 
cardiovascular disorders); (b) known or suspected history of al-
coholism, drug dependence and abuse, head trauma, and mental 
disorders (apart from mood or anxiety disorders) according to 
the Diagnostic and Statistical Manual of Mental Disorders—Fifth 
Edition (DSM-5); (c) the presence of vascular brain lesions, brain 
tumor, and/or marked cortical and subcortical atrophy on CT and/
or MRI scan.
The study was approved by the Ethical Committee of 
Fondazione Santa Lucia IRCCS, and, in accordance with the 
Helsinki Declaration, each subject signed an informed consent 
form prior to enrollment.
2.2 | Neurological, psychiatric, and 
neuropsychological examinations
Sociodemographic and clinical data were collected by neurologists 
during the clinical examination. The evaluation of motor symptoms 
was made using the UPDRS-III, and disease stage was measured by 
the modified Hoehn and Yahr (H & Y) scale.
All patients underwent a Structured Clinical Interview for DSM-5 
Disorders—Clinician Version (SCID-5-CV) for the identification of 
psychiatric disorders according to the DSM-5 criteria. Psychiatric 
diagnoses were made by a senior psychiatrist.
The severities of symptoms of depression, anxiety, apathy, 
anhedonia, and alexithymia were quantified in all subjects by the 
Hamilton Depression Rating Scale (HDRS), the Hamilton Anxiety 
Rating Scale (HARS), the Apathy Rating Scale (ARS), the Snaith–
Hamilton Pleasure Scale (SHAPS), and the Toronto Alexithymia 
Scale-20 item (TAS-20), respectively (Bagby, Taylor, & Parker, 1994; 
Pontieri et al., 2015). In particular, the SHAPS is a self-rated instru-
ment that consists of 14 items covering the domains of social in-
teraction, food and drink, sensory experiences, achievement, and 
pastimes. The subject is requested to agree or disagree with a state-
ment in each item on a Likert scale (definitely agree, agree, disagree, 
and definitely disagree). The four available answers are divided into 
dichotomous categories (agree = 0; disagree = 1), ranging from 0 to 
14 and with a cut-off score of 2 as the best discrimination between 
“normal” (a score of 2 or less was categorized as hedonic) and “ab-
normal” (a score above 2 was categorized as anhedonic) level of 
hedonic	 tone.	 The	 TAS-20	 is	 a	 self−	 report	 instrument	 that	 has	
good internal consistency and good reliability as well as construct 
and criterion validity for the measurement of alexithymic charac-
teristics. It comprises three subscales that assess distinct facets 
of alexithymia: F1, difficulty identifying feelings; F2, difficulty 
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describing feelings; and F3, an externally oriented analytic mode 
of thinking. To evaluate the prevalence of alexithymia, patients 
with a TAS-20 score greater than 60 were considered alexithymic, 
whereas patients ranging from 52 to 60 were considered as bor-
derline alexithymic and those scoring less than 52 were considered 
non alexithymic.
Further, all participants underwent a complete neuro-
psychological examination (Pontieri et al., 2015) including 
(a) MMSE as global index of cognitive impairment; (b) the 
Mental Deterioration Battery, a comprehensive neuropsycho-
logical battery that includes verbal and nonverbal tasks such 
as (a) Rey’s 15-word test Immediate Recall (RIR) to evaluate 
short- and long-term verbal memory, and Delayed Recall (RDR) 
to evaluate long-term verbal memory; (b) Phonologic (PVF) and 
Semantic (SVF) Verbal Fluency tests to assess language abil-
ity; Copy of the Rey–Osterrieth picture (CRO) and Delayed 
Recall of the Rey–Osterrieth picture (DRO) to evaluate complex 
constructional praxis and long-term visual memory; Wisconsin 
Card Sorting Test—Short Form (WCST-SF), to explore exec-
utive functions; and Stroop Word–Color Test (SWCT) to as-
sess frontal abilities of simple attention, attention shifting, and 
control.
2.3 | Statistical analysis
The distribution of the analyzed factors was verified using the 
Shapiro–Wilk test. Group comparisons for sociodemographic, neu-
rological, psychiatric, and cognitive variables were performed using 
ANOVA or, in the case of non-normal distributions, Kruskal–Wallis 
for continuous variables and chi-square tests for categorical vari-
ables, followed by Fisher’s protected least significant difference 
(PLSD) and Fisher’s exact test for post hoc comparisons when 
appropriate.
The level of statistical significance was defined as p < 0.05.
TA B L E  1   Sociodemographic, neurological, and psychiatric characteristics of the study cohort
AR (n = 39) 
Mean ± SD
TD (n = 22) 
Mean ± SD
MIX (n = 7) 
Mean ± SD F df p
Sociodemographic and neurological characteristics
Age (years) 63.7	±	9.8 63.4	±	9.8 64.7	±	12.5 0.045 2 0.956
Age at symptom onset 
(years)
63.0	±	9.8 62.8	±	9.7 64.0	±	12.5 0.040 2 0.961
Duration of illness (years) 0.7	±	0.5 0.6	±	0.6 0.7	±	0.5 0.058 2 0.943
Education (years) 11.4	±	4.8 12.1	±	3.7 15.0	±	2.2 2.119 2 0.128
UPDRS-III 13.3	±	8.0 12.9	±	8.1 18.3	±	10.2 1.246 2 0.294
H & Y 1.5	±	0.5 1.4	±	0.5 1.8	±	0.6 1.852 2 0.232
n (%) n (%) n (%) χ2a p
Gender (male) 29	(74.4) 12 (54.5) 3 (42.9) 4.049 2 0.132
n (%) n (%) n (%) χ2a p
Frequency of psychiatric diagnoses
Major depressive disorder 1 (2.6) 0 (0.0) 0 (0.0) 3.577 4 0.4663
Minor depressive disorder 10 (25.6) 6	(27.3) 4	(57.1)
No depressive disorder 28	(71.8) 16	(72.7) 3 (42.8)
Generalized anxiety 
disorder
1 (2.6) 3 (13.6) 1 (14.3) 3.082 2 0.2142
Anhedonia 0 (0.0) 0 (0.0) 0 (0.0) – – –
Alexithymia 6 (15.4) 0 (0.0) 1 (14.3) 3.740 2 0.1541
Apathy 1 (2.6) 0 (0.0) 0 (0.0) 0.755 2 0.6857
Frequency of psychiatric drugs
Antidepressant drugs (%) 3	(7.7) 0 (0) 0 (0) 2.255 2 0.3239
Benzodiazepine (%) 6 (15.4) 2 (9) 2 (28.6) 2.197 2 0.333
Antipsychotic drugs (%) 0 (0) 0 (0) 0 (0) – – –
Notes. AR: akinetic-rigid PD subtype; df: degrees of freedom; MIX: mixed PD subtype; SD: standard deviation; TD: tremor-dominant PD subtype; 
UPDRS-III: Unified Parkinson’s Disease Rating Scale – Part III; H &Y: Hoehn and Yahr scale.
aResults of all chi-square analyses were confirmed using Fisher’s exact test by pairwise comparisons showing no differences (p	>	0.786	for	all	compar-
isons) between groups. 
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3  | RESULTS
Table 1 shows the sociodemographic and clinical characteristics of 
the study populations.
Akinetic-rigid, TD, and MIX PD subgroups did not differ signifi-
cantly in any of these variables.
The three groups of patients with PD did not significantly differ 
in scores and frequency of psychiatric diagnosis, and in any cognitive 
scores (Table 2).
4  | DISCUSSION
To our knowledge, this is the first study that investigated the com-
prehensive psychiatric profile of different motor subtypes of de 
novo drug-naïve patients with PD. The design of our study offers the 
opportunity to exclude confounding factors, such as mixed disease 
duration or drug treatment, that might affect results. Under these 
circumstances, we did not find differences in psychiatric character-
istics at the clinical onset among the three motor phenotypes. It is 
AR (n = 39) 
Mean ± SD
TD (n = 22) 
Mean ± SD
MIX (n = 7) 
Mean ± SD F df p
Psychiatric scores
Hamilton Depression 
Rating Scale
7.2	±	3.8 7.2	±	3.7 9	±	3.3 0.823 2 0.444
Hamilton Anxiety 
Rating Scale
6.8	±	3.3 7.4	±	4.8 10.0	±	5.1 1.919 2 0.155
Apathy Rating Scale 6.7	±	5.0 6.7	±	4.2 10.3	±	2.6 3.971 2 0.165
Snaith–Hamilton 
Pleasure Scale
0.2	±	0.5 0.2	±	0.4 0.0	±	0.0 0.850 2 0.432
TAS-20—total 44.7	±	12.5 43.9	±	9.5 46.3	±	12.8 0.108 2 0.897
TAS-20—difficulty in 
identifying feelings 
(F1)
11.5	±	5.6 12.2	±	5.8 13.6	±	6.1 0.412 2 0.664
TAS-20—difficulty in 
describing feelings 
(F2)
13.0	±	6.2 12.9	±	5.1 12.1	±	4.2 0.065 2 0.937
TAS-20—externally 
oriented thinking (F3)
20.2	±	5.6 18.8	±	5.6 20.6	±	4.9 0.525 2 0.594
Neuropsychological scores
MMSE 28.5	±	2.0 28.9	±	1.4 29.4	±	1.1 0.986 2 0.379
Rey’s 15-word 
test—Immediate Recall
38.3	±	11.1 40.9	±	12.4 37.6	±	8.3 0.420 2 0.658
Rey’s 15-word 
test—Delayed Recall
7.9	±	3.7 8.8	±	4.0 7.4	±	2.7 0.599 2 0.552
Copy of the Rey–
Osterrieth picture
29.1	±	6.1 30.0	±	5.4 31.4	±	3.6 0.578 2 0.564
Delayed Recall of the 
Rey–Osterrieth 
picture
16.2	±	6.5 17.1	±	7.1 13.1	±	6.6 0.978 2 0.382
SWCT—word reading 
(sec)
15.8	±	5.4 14.4	±	2.8 14.7	±	2.9 0.705 2 0.498
SWCT—color naming 
(sec)
21.4	±	8.1 19.6	±	4.4 20.7	±	4.0 0.491 2 0.614
SWCT—interference 
time (sec)
42.0	±	13.0 38.5	±	11.8 38.6	±	14.2 0.620 2 0.541
WCST-SF—categories 5.4	±	1.3 5.5	±	1.1 6.0	±	0.0 0.717 2 0.492
WCST-SF—persevera-
tive errors
2.7	±	3.7 2.5	±	4.4 1.4	±	0.8 0.347 2 0.708
WCST-SF—nonperse-
verative errors
3.0	±	2.9 2.0	±	2.8 1.6	±	1.1 1.245 2 0.295
Notes. AR: akinetic-rigid PD subtype; df: degrees of freedom; MIX: mixed PD subtype; MMSE: Mini-
Mental State Examination; SD: standard deviation; SWCT: Stroop Word–Color Test; TD: tremor-
dominant PD subtype; WCST-SF: Wisconsin Card Sorting Test—Short Form.
TA B L E  2   Psychiatric and 
neuropsychological scale scores of the 
study cohort
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interesting that our findings diverge from the few previous studies 
investigating this topic. In particular, our results differ from those 
of two reports by Poletti et al. (2012, 2011) that partially evaluated 
the psychiatric characteristics (depression and alexithymia) of de 
novo untreated patients with PD and extensively evaluated their 
cognitive functioning (Poletti et al., 2012). They found that the 
PIGD motor subtype was associated with alexithymic features and 
impairment in language abilities compared to TD. A possible ex-
planation of these discrepancies lies in the different classification 
of motor subtypes and in patient’s disease duration, very short in 
our sample. In particular, we utilized the classification of Kang et al. 
(2005) that is the most adequate method for classifying patients in 
the early stage of PD. On the contrary, the classifications used by 
Poletti et al. (2012, 2011) consider other hallmarks, such as falls 
and postural instability, that are more frequent in moderate and 
advanced stages of PD.
On the contrary, our results on cognitive features are in line with 
more recent findings. Pont-Sunyer et al. (2015), in a study with a 
cluster design, based on a custom-made questionnaire, did not find 
relationship between specific motor phenotype or severity and any 
of the early non-motor symptom clusters identified (Pont-Sunyer 
et al., 2015). Domellof et al. (2011) did not find cognitive differences 
among motor phenotypes in de novo drug-naïve patients with PD, 
investigated with an extensive neuropsychological battery.
We hypothesize that, in the very early stage of the disease, 
psychiatric differences among the three motor subtypes of PD are 
not detectable, suggesting that these symptoms or profiles emerge 
and become clinically evident over the progression of PD. This idea 
is widely supported by the literature on PD patients with longer 
disease duration and under antiparkinsonian treatment showing 
greater cognitive deterioration and psychiatric symptoms in AR pa-
tients (Moustafa & Poletti, 2013), moreover, it is in part supported by 
few studies conducted on de novo patients with PD.
We also acknowledge our study limitations. The diagnosis of 
our patients has not been confirmed by pathological evidence but 
only by clinical examinations and positive responses to dopaminer-
gic therapy. In fact, all patients were diagnosed by independent and 
very expert movement disorders specialists, both at baseline and 
at follow-up visits performed after 12, 24, and 36 months, when 
the definitive effect of dopaminergic treatment can be evaluated. 
Further, we do recognize that our results are obtained in a relatively 
small sample size. In particular, the mixed group includes only seven 
patients that we have decided to keep in our classification to give a 
more naturalistic picture of our study cohort.
In conclusion, here we showed that in the early stage of PD, the 
different motor subtypes are not associated with a specific psy-
chiatric profile, suggesting that a possible differentiation emerges 
only over the progression of the disease and potentially with its 
interaction with dopaminergic replacing therapy. Therefore, the 
evolution of psychiatric features is not predictable based on 
early motor presentation and regular follow-ups are needed to 
investigate their different possible progression. Further studies 
on larger samples and investigating at which point of the disease 
course the motor subtypes start to diverge are strongly needed.
ACKNOWLEDG MENTS
This work was supported by grants RC09-10-11-12-13-14/A from 
Italian Ministry of Health to GS and PAMINA project from Regione 
Lazio to FA.
CONFLIC T OF INTERE S T
The authors declare that there is no conflict of interest.
AUTHORS’  CONTRIBUTIONS
Assogna, Pellicano, Cravello, Savini, Pierantozzi, Mercuri, Pontieri, 
Caltagirone, Spalletta, and Stefani substantially contributed to con-
ception and design, acquisition of data, and analysis and interpreta-
tion of data; drafted the article or revised it critically for important 
intellectual content; and contributed to the final approval of the ver-
sion to be submitted.
ORCID
Francesco E. Pontieri  http://orcid.org/0000-0002-8693-8432 
Gianfranco Spalletta  http://orcid.org/0000-0002-7432-4249   
R E FE R E N C E S
Bagby,	R.	M.,	Taylor,	G.	J.,	&	Parker,	J.	D.	(1994).	The	Twenty-item	Toronto	
Alexithymia Scale–II. Convergent, discriminant, and concurrent va-
lidity. Journal of Psychosomatic Research, 38, 33–40. https://doi.
org/10.1016/0022-3999(94)90006-X
Domellof, M. E., Elgh, E., & Forsgren, L. (2011). The relation between 
cognition and motor dysfunction in drug-naive newly diagnosed pa-
tients with Parkinson’s disease. Movement Disorders, 26, 2183–2189. 
https://doi.org/10.1002/mds.23814
Kang,	 G.	 A.,	 Bronstein,	 J.	 M.,	 Masterman,	 D.	 L.,	 Redelings,	 M.,	
Crum,	 J.	 A.,	 &	 Ritz,	 B.	 (2005).	 Clinical	 characteristics	 in	 early	
Parkinson’s disease in a central California population-based study. 
Movement Disorders, 20, 1133–1142. https://doi.org/10.1002/
(ISSN)1531-8257
Moustafa, A. A., & Poletti, M. (2013). Neural and behavioral substrates 
of subtypes of Parkinson’s disease. Frontiers in Systems Neuroscience, 
7,	117.
Oh,	 J.	 Y.,	 Kim,	 Y.	 S.,	 Choi,	 B.	 H.,	 Sohn,	 E.	 H.,	 &	 Lee,	 A.	 Y.	 (2009).	
Relationship between clinical phenotypes and cognitive impairment 
in Parkinson’s disease (PD). Archives of Gerontology and Geriatrics, 49, 
351–354. https://doi.org/10.1016/j.archger.2008.11.013
Poletti, M., Frosini, D., Pagni, C., Baldacci, F., Nicoletti, V., Tognoni, G., 
… Bonuccelli, U. (2012). Mild cognitive impairment and cognitive-
motor relationships in newly diagnosed drug-naive patients with 
Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 
83,	601–606.	https://doi.org/10.1136/jnnp-2011-301874
Poletti, M., Frosini, D., Pagni, C., Lucetti, C., Del Dotto, P., Ceravolo, R., 
& Bonuccelli, U. (2011). Alexithymia is associated with depression in 
6 of 6  |     ASSOGNA et Al.
de novo Parkinson’s disease. Psychotherapy and Psychosomatics, 80, 
251–253. https://doi.org/10.1159/000322029
Pontieri, F. E., Assogna, F., Pellicano, C., Cacciari, C., Pannunzi, S., 
Morrone, A., … Spalletta, G. (2015). Sociodemographic, neuropsy-
chiatric and cognitive characteristics of pathological gambling and 
impulse control disorders NOS in Parkinson’s disease. European 
Neuropsychopharmacology, 25,	 69–76.	 https://doi.org/10.1016/j.
euroneuro.2014.11.006
Pont-Sunyer, C., Hotter, A., Gaig, C., Seppi, K., Compta, Y., Katzenschlager, 
R., … Tolosa, E. (2015). The onset of nonmotor symptoms in 
Parkinson’s disease (the ONSET PD study). Movement Disorders, 30, 
229–237.	https://doi.org/10.1002/mds.26077
Rajput, A. H., Sitte, H. H., Rajput, A., Fenton, M. E., Pifl, C., & 
Hornykiewicz, O. (2008). Globus pallidus dopamine and 
Parkinson motor subtypes: Clinical and brain biochemical cor-
relation. Neurology, 70, 1403–1410. https://doi.org/10.1212/ 
01.wnl.0000285082.18969.3a
Rajput, A. H., Voll, A., Rajput, M. L., Robinson, C. A., & Rajput, A. (2009). Course in 
Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology, 
73,	206–212.	https://doi.org/10.1212/WNL.0b013e3181ae7af1
Sauerbier,	A.,	Jenner,	P.,	Todorova,	A.,	&	Chaudhuri,	K.	R.	(2016).	Non	motor	
subtypes and Parkinson’s disease. Parkinsonism & Related Disorders, 
22(Suppl	1),	S41–S46.	https://doi.org/10.1016/j.parkreldis.2015.09.027
Zaidel, A., Arkadir, D., Israel, Z., & Bergman, H. (2009). Akineto-rigid vs. 
tremor syndromes in Parkinsonism. Current Opinion in Neurology, 22, 
387–393.	https://doi.org/10.1097/WCO.0b013e32832d9d67
How to cite this article: Assogna F, Pellicano C, Cravello L, 
et al. Psychiatric profile of motor subtypes of de novo drug-
naïve Parkinson’s disease patients. Brain Behav. 
2018;8:e01094. https://doi.org/10.1002/brb3.1094
